Progression/relapse · Patients with untreated Hodgkin lymphoma (advanced stages)
Dose‐intensified chemotherapy probably leads to lower progression/relapse compared with ABVD‐like chemotherapy (with or without radiotherapy (moderate certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Local recurrence · breast‐conserving radiotherapy for breast cancer
Boost may leads to lower local control: recurrence at 5 years compared with no boost (low certainty).
1 finding from 1 review
Overall survival: mortality at 5 years · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in overall survival: mortality at 5 years compared with no boost (moderate certainty).
1 finding from 1 review
Disease-free survival (new disease, progression or mortality) · breast‐conserving radiotherapy for breast cancer
Boost showed no clear difference in disease‐free survival: disease progression/mortality at 5 years compared with no boost (low certainty).
1 finding from 1 review
Late toxicity, pBRA · breast‐conserving radiotherapy for breast cancer
It is very uncertain whether boost changes late toxicity, pBRA compared with no boost (very low certainty).
1 finding from 1 review
Cosmesis · breast‐conserving radiotherapy for breast cancer
Boost may leads to higher cosmesis, panel scored: fair or poor compared with no boost (low certainty).
2 findings from 1 review
Sensitivity analysis: local control ‐ recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower sensitivity analysis: local control ‐ recurrence at 5 years compared with no boost (high certainty).
1 finding from 1 review
Subgroup analysis: local control ‐ > 40 years old, recurrence at 5 years · breast‐conserving radiotherapy for breast cancer
Boost leads to lower subgroup analysis: local control ‐ > 40 years old, recurrence at 5… compared with no boost (high certainty).
1 finding from 1 review
Nausea · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
1 finding from 1 review
Number of vomiting episodes · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient satisfaction · participants with advanced cancer who have nausea and vomiting not related to chemotherapy, radiotherapy, or surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dysphagia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in dysphagia compared with placebo; GRADE not reported.
1 finding from 1 review
RR 1.32 [0.55, 3.13]
3 studies
GRADE not reported
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in locoregional tumour control compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Nausea · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge led to higher nausea (adverse effect) compared with placebo; GRADE not reported.
1 finding from 1 review